Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i editorial
13 June 2016

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Remnant cholesterol back in the newsRead more...

Despite emphasis on low-density lipoprotein cholesterol (LDL-C) as the primary lipid target, reinforced by publication of the Sixth Joint Task Force European Guidelines for Cardiovascular Disease Prevention in Clinical Practice this month, it is increasingly clear that individuals with well controlled LDL-C levels are still at high residual risk of cardiovascular events.
 
A proportion of this risk is undoubtedly lipid-related, given that the INTERHEART study showed that dyslipidaemia was one of the top nine factors associated with risk for myocardial infarction. The question remains: what other lipid measures should be taken into account for assessment of residual cardiovascular risk?
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
13 June 2016

Remnant cholesterol levels are predictive of coronary heart disease in primary prevention patientsRead more...

The results of this analysis provide further support for remnant lipoprotein cholesterol as an independent contributor to lipid-related cardiovascular risk. Indeed, in the combined analysis, each standard deviation increase in remnant cholesterol was associated with 23% increase in risk of CHD. These findings are consistent...
focus on...
13 June 2016

Genetic study provides support for targeting atherogenic cholesterol beyond that carried by LDL particles to reduce residual cardiovascular riskRead more...

Non-HDL-C is defined as total cholesterol minus HDL-C, and thus incorporates the cholesterol from triglyceride-rich lipoproteins (which encompasses very low-density lipoprotein, chylomicrons, and their cholesterol-enriched remnants), as well as LDL-C. In this study, causality analysis using genetic risk scores based on 27 rare and low-frequency...
recent publication

ASGR1; the next PCSK9 story?Read more...

This study, involving data from 2636 Icelandic subjects, focused on...
recent publication

HDL mimetic peptide CER-522 improves left ventricular diastolic dysfunctionRead more...

In this experimental study in rabbits, the HDL mimetic CER-522...
recent publication

Triglycerides predictive of arterial stiffnessRead more...

Arterial stiffness is strongly predictive of atherosclerotic cardiovascular disease. In...
recent publication

Lipid-lowering for primary cardiovascular prevention in type 1 diabetesRead more...

Findings from the Swedish National Diabetes Register show the importance...
recent publication

Homocysteine levels are not associated with an atherogenic lipid profileRead more...

Hyperhomocysteinaemia is an independent risk factor for cardiovascular disease, although...
recent publication

Triglyceride/HDL-C ratio: indicator of risk of sleep apnoea syndromeRead more...

The ratio of serum triglycerides to high-density lipoprotein cholesterol (TG/HDL-C)...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.